These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27662429)

  • 1. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
    Mensing S; Eckert D; Sharma S; Polepally AR; Khatri A; Podsadecki TJ; Awni WM; Menon RM; Dutta S
    Br J Clin Pharmacol; 2017 Mar; 83(3):527-539. PubMed ID: 27662429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
    Polepally AR; Badri PS; Eckert D; Mensing S; Menon RM
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):333-339. PubMed ID: 27165046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.
    Zha J; Ding B; Wang H; Zhao W; Yu C; Alves K; Mobashery N; Luo Y; Menon RM
    Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):43-52. PubMed ID: 29909549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials.
    Polepally AR; Badri PS; Parikh A; Rodrigues L; Da Silva-Tillmann BA; Mensing S; Podsadecki TJ; Awni WM; Dutta S; Menon RM
    Antivir Ther; 2016; 21(8):707-714. PubMed ID: 27584548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.
    Smith MA; Lim A
    Drug Des Devel Ther; 2015; 9():6083-94. PubMed ID: 26622169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
    Khatri A; Menon RM; Marbury TC; Lawitz EJ; Podsadecki TJ; Mullally VM; Ding B; Awni WM; Bernstein BM; Dutta S
    J Hepatol; 2015 Oct; 63(4):805-12. PubMed ID: 26070406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
    Deeks ED
    Drugs; 2015 Jun; 75(9):1027-38. PubMed ID: 26059288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
    King JR; Khatri A; Trinh R; Viani RM; Ding B; Zha J; Menon R
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
    Klibanov OM; Gale SE; Santevecchi B
    Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies.
    Gopalakrishnan S; Mensing S; Menon RM; Zha J
    Clin Pharmacokinet; 2018 Nov; 57(11):1407-1419. PubMed ID: 29516428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world.
    Tempestilli M; Fabbri G; Mastrorosa I; Timelli L; Notari S; Bellagamba R; Libertone R; Lupi F; Zaccarelli M; Antinori A; Agrati C; Ammassari A
    J Antimicrob Chemother; 2018 Jan; 73(1):160-164. PubMed ID: 29106584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
    Khatri A; Mensing S; Podsadecki T; Awni W; Menon R; Dutta S
    Clin Drug Investig; 2016 Aug; 36(8):625-35. PubMed ID: 27153823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies.
    Mensing S; Polepally AR; König D; Khatri A; Liu W; Podsadecki TJ; Awni WM; Menon RM; Dutta S
    AAPS J; 2016 Jan; 18(1):270-80. PubMed ID: 26597291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
    Polepally AR; King JR; Ding B; Shuster DL; Dumas EO; Khatri A; Chiu YL; Podsadecki TJ; Menon RM
    Clin Pharmacokinet; 2016 Aug; 55(8):1003-14. PubMed ID: 26895022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.
    Gopalakrishnan SM; Polepally AR; Mensing S; Khatri A; Menon RM
    Clin Pharmacokinet; 2017 Jan; 56(1):1-10. PubMed ID: 27314261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.
    Badri PS; Dutta S; Wang H; Podsadecki TJ; Polepally AR; Khatri A; Zha J; Chiu YL; Awni WM; Menon RM
    Antimicrob Agents Chemother; 2016 Jan; 60(1):105-14. PubMed ID: 26459906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.
    Badri P; Dutta S; Coakley E; Cohen D; Ding B; Podsadecki T; Bernstein B; Awni W; Menon R
    Am J Transplant; 2015 May; 15(5):1313-22. PubMed ID: 25708713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
    Khatri A; Dutta S; Wang H; Podsadecki T; Trinh R; Awni W; Menon R
    Clin Infect Dis; 2016 Apr; 62(8):972-9. PubMed ID: 26740513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
    Polepally AR; Mensing S; Khatri A; Beck D; Liu W; Awni WM; Menon RM; Dutta S
    Clin Pharmacokinet; 2016 Sep; 55(9):1091-101. PubMed ID: 27000758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.
    Khatri A; Dutta S; Marbury TC; Preston RA; Rodrigues L; Wang H; Awni WM; Menon RM
    Clin Pharmacokinet; 2017 Feb; 56(2):153-163. PubMed ID: 27389403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.